Disease · EFO_0007948
HIV-associated neurocognitive disorder
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. HIV-associated neurocognitive disorder. Diseases, record EFO_0007948. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0007948
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- HIV-associated neurocognitive disorder
- Open Targets ID
- EFO_0007948
- Other names
- HAND
- Highest stage of its drugs
- Phase 3, for 1 of its 11 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs11
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| METHYLPHENIDATE | CHEMBL796 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| MARAVIROC | CHEMBL256907 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| INSULIN HUMAN | CHEMBL1201631 | Protein | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| BARICITINIB | CHEMBL2105759 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| CENICRIVIROC | CHEMBL2110727 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| GALANTAMINE | CHEMBL659 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| FLUCONAZOLE | CHEMBL106 | Small molecule | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PAROXETINE | CHEMBL490 | Small molecule | Phase 1/2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ANAKINRA | CHEMBL1201570 | Protein | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| MECAMYLAMINE | CHEMBL267936 | Small molecule | Unknown | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 11
See all 11 drugsTargets13
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| CCR5 | C-C chemokine receptor type 5 | 2 | C-C chemokine receptor type 5 antagonist | Phase 2/3 | https://conductscience.org/library/genes/1234 | Drugs and targets |
| ACHE | Acetylcholinesterase | 1 | Acetylcholinesterase inhibitor | Phase 2 | https://conductscience.org/library/genes/43 | Drugs and targets |
| CCR2 | C-C chemokine receptor type 2 | 1 | C-C chemokine receptor type 2 antagonist | Phase 2 | https://conductscience.org/library/genes/729230 | Drugs and targets |
| CHRM1 | Muscarinic acetylcholine receptor M1 | 1 | Muscarinic acetylcholine receptor M1 antagonist | Unknown | https://conductscience.org/library/genes/1128 | Drugs and targets |
| CHRNA3 | Neuronal acetylcholine receptor; alpha3/beta4 | 1 | Neuronal acetylcholine receptor; alpha3/beta4 negative allosteric modulator | Unknown | https://conductscience.org/library/genes/1136 | Drugs and targets |
| CHRNB4 | Neuronal acetylcholine receptor; alpha3/beta4 | 1 | Neuronal acetylcholine receptor; alpha3/beta4 negative allosteric modulator | Unknown | https://conductscience.org/library/genes/1143 | Drugs and targets |
| IL1R1 | Interleukin-1 receptor type 1 | 1 | Interleukin-1 receptor antagonist | Phase 1 | https://conductscience.org/library/genes/3554 | Drugs and targets |
| INSR | Insulin receptor | 1 | Insulin receptor agonist | Phase 2 | https://conductscience.org/library/genes/3643 | Drugs and targets |
| JAK1 | Tyrosine-protein kinase JAK1 | 1 | Tyrosine-protein kinase JAK1 inhibitor | Phase 2 | https://conductscience.org/library/genes/3716 | Drugs and targets |
| JAK2 | Tyrosine-protein kinase JAK2 | 1 | Tyrosine-protein kinase JAK2 inhibitor | Phase 2 | https://conductscience.org/library/genes/3717 | Drugs and targets |
1 to 10 of 13
See all 13 targetsTrials10
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03384784 | Effect of Galantamine on Inflammation and Cognition | Phase 2 | 63 | 2024-10-17 | HIV Associated Cognitive Motor Complex | GALANTAMINE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT01354314 | Study of Paroxetine and Fluconazole for the Treatment of HIV Associated Neurocognitive Disorder | Phase 1/2 | 45 | 2017-05-12 | HIV Associated Neurocognitive Disorder | FLUCONAZOLE, PAROXETINE | Its record names the disease | ClinicalTrials.gov |
| NCT03081117 | Intranasal Insulin for the Treatment of HAND | Phase 1/2 | 21 | 2021-07-07 | HIV Dementia, HIV-Associated Cognitive Motor Complex | INSULIN HUMAN | Its record names the disease | ClinicalTrials.gov |
| NCT02128828 | Effect of Cenicriviroc on HIV Neurocognitive Impairment | Phase 2 | 20 | 2020-08-20 | AIDS Dementia Complex, HIV-1-Associated Cognitive Motor Complex, Human Immunodeficiency Virus | CENICRIVIROC | Its record names the disease | ClinicalTrials.gov |
| NCT05452564 | Baricitinib for Reduction of HIV - CNS | Phase 2 | 95 | Human Immunodeficiency Virus | BARICITINIB | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT02159027 | Maraviroc and NeuroAIDS Pathogenesis | Phase 2/3 | 48 | AIDS Dementia Complex | MARAVIROC | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT01599975 | A Study Comparing Long-acting Methylphenidate (ConcertaTM) vs. Placebo in the Treatment of Memory Loss Due to HIV | Phase 3 | 40 | HIV Dementia | METHYLPHENIDATE | Its record names the disease | ClinicalTrials.gov | |
| NCT03244488 | Mental Ability Challenge Study in Adults With and Without HIV | 22 | HIV-1-infection, Aging, Premature, Cognitive Impairment, Memory Impairment, HIV-Associated Cognitive Motor Complex | MECAMYLAMINE, SCOPOLAMINE | Open Targets' reading of its record | ClinicalTrials.gov | ||
| NCT03277222 | Intranasal Treatment of HIV-associated Neurocognitive Disorders | Phase 2 | 4 | HIV Associated Neurocognitive Disorder (HAND) | INSULIN HUMAN | Its record names the disease | ClinicalTrials.gov | |
| NCT02527460 | Anakinra, A Recombinant Human IL-1 Receptor Antagonist for Neuroinflammation in HIV-1 Infection | Phase 1 | 1 | HIV Infections, Neurologic Disorders | ANAKINRA | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials2
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Insulin, Intranasal vs Placebo, Intranasal: deaths from any cause | 0 of 10 | 0 of 11 | 21 | NCT03081117 | Trial comparisons |
| Insulin, Intranasal vs Placebo, Intranasal: serious adverse events | 2 of 10 | 2 of 11 | 21 | NCT03081117 | Trial comparisons |
Papers from its trials2
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/EFO_0007948
GET https://conductscience.org/api/diseases/v1/EFO_0007948/drugs